X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.pharmaceutical-technology.com/news/fda-takeda-entyvio-sc/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761133
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761133
https://www.prnewswire.com/news-releases/polpharma-biologics-investigational-biosimilar-shows-pkpd-comparability-to-inflammatory-bowel-disease-blockbuster-entyvio-302066341.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761133
https://www.fiercebiotech.com/biotech/morphics-stock-sinks-data-oral-entyvio-rival-disappoints#:~:text=In%20the%20hours%20leading%20up,topline%20data%20release%20in%20April.
https://www.biopharmadive.com/news/morphic-ulcerative-colitis-study-results-oral-entyvio/648524/
https://www.takeda.com/newsroom/newsreleases/2023/approval-to-manufacture-and-market-entyvio
https://www.reuters.com/markets/deals/takeda-buy-inflammatory-disease-drug-4-bln-nimbus-2022-12-13/
https://www.fiercebiotech.com/biotech/not-ideal-protagonist-sinks-high-dose-oral-entyvio-rival-fails-ulcerative-colitis#:~:text=Protagonist%20Therapeutics%20has%20failed%20to,sent%20the%20stock%20spiraling%20downward.
https://www.takeda.com/newsroom/newsreleases/2021/takeda-receives-positive-chmp-opinion-for-vedolizumab-iv-for-the-treatment-of-active-chronic-pouchitis/
https://www.europeanpharmaceuticalreview.com/news/165592/crohns-patients-achieve-65-percent-clinical-remission-with-tremfya/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125476
https://www.takeda.com/newsroom/newsreleases/2020/safety-and-efficacy-of-subcutaneous-entyvio-vedolizumab-sustained-during-long-term-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis/
https://www.takeda.com/newsroom/newsreleases/2020/takeda-receives-u.s.-fda-approval-to-manufacture-entyvio-vedolizumab-drug-substance-at-manufacturing-facility-in-brooklyn-park-minnesota/#:~:text=Cambridge%2C%20MASSACHUSETTS%20and%20Osaka%2C%20JAPAN,Brooklyn%20Park%2C%20Minnesota%20for%20the
http://www.pharmatimes.com/news/final_nice_green_light_for_janssens_stelara_in_uc_1342426
https://www.prnewswire.com/news-releases/despite-increased-competition-from-the-recent-launch-of-janssens-stelara-takedas-entyvio-continues-to-shine-as-a-leading-ulcerative-colitis-treatment-301068361.html
https://www.takeda.com/newsroom/newsreleases/2020/european-commission-approves-subcutaneous-entyvio-for-use-as-maintenance-therapy-in-ulcerative-colitis-or-crohns-disease/
http://www.pharmafile.com/news/544381/china-approves-takeda-s-treatment-ulcerative-colitis-and-crohn-s-disease
https://www.nasdaq.com/articles/takeda%3A-subcutaneous-formulation-of-vedolizumab-receives-positive-chmp-opinion-2020-02-28
http://www.pharmafile.com/news/541698/strong-phase-3-data-takedas-entyvio-combo-moderate-severe-crohns-disease
http://www.pharmatimes.com/news/subcutaneous_entyvio_hits_crohns_primary_endpoint,_misses_secondary_1326192
https://www.afp.com/en/news/1316/investigational-subcutaneous-formulation-vedolizumab-achieves-clinical-remission-week-52-patients-moderately-severely-active-crohns-disease-202002140053001
http://www.pmlive.com/pharma_news/takedas_subcutaneous_entyvio_formulation_faces_fda_rejection_1320841
https://endpts.com/zealand-takes-on-takedas-ibd-drug-with-tiny-buyout/
https://www.clinicaltrialsarena.com/news/takeda-reports-results-varsity-study/
http://www.pharmatimes.com/news/entyvio_beats_humira_in_head-to-head_ulcerative_colitis_trial_1302825
https://www.biospace.com/article/subcutaneous-formulation-of-takeda-s-entyvio-hits-the-mark-in-crohn-s-trial/
https://www.fiercepharma.com/pharma/goodbye-deerfield-takeda-sets-december-deadline-for-reassignment-1-000-u-s-employees
http://www.pharmafile.com/news/522383/takeda-scores-japanese-entyvio-approval-crohns-disease
http://www.pharmafile.com/news/522314/takedas-entyvio-beats-humira-remission-ulcerative-colitis-exploratory-data-show
https://www.fiercepharma.com/pharma/new-velcade-rival-looming-uloric-patent-loss-to-cost-post-shire-takeda-growth
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125476
http://www.pharmatimes.com/news/ema_accepts_takeda_application_for_subcutaneous_entyvio_1283242
https://endpts.com/ftc-demands-more-info-from-bristol-myers-celgene-on-psoriasis-drugs-signaling-a-potential-hitch-for-74b-deal/
http://www.pmlive.com/pharma_news/takedas_entyvio_tops_humira_in_ulcerative_colitis_1281066
https://www.fiercepharma.com/pharma/takeda-cheers-strong-growth-from-key-drugs-despite-ninlaro-fda-snag
Market Place
Share 
